European Academy of Dermatology and Venereology Congress

The latest news out of the European Academy of Dermatology and Venereology Congress with physician perspective, researcher interviews and clinician insight.

Meeting News

Patients with pemphigus vulgaris more likely to achieve sustained complete remission with Rituxan

October 23, 2019
Rituxan met a primary endpoint and demonstrated it is superior to mycophenolate mofetil in adults with moderate to severe pemphigus vulgaris in the…
Meeting News

Ruxolitinib cream improves repigmentation of vitiligo at 52 weeks

October 21, 2019
Among patients with vitiligo, treatment with ruxolitinib cream resulted in substantial improvements in total-body repigmentation at week 52 assessed…
Meeting News

Long-term disease activity minimal with Cimzia in psoriatic arthritis trial

October 21, 2019
Patients with psoriatic arthritis showed long-term efficacy and safety with Cimzia by achieving Disease Activity Index for Psoriatic Arthritis…
Meeting News

Taltz improves skin, itch, QoL in pediatric patients with psoriasis

October 17, 2019
Phase 3 data presented at the European Academy of Dermatology and Venereology Congress demonstrated that treatment with Taltz resulted in a 75%…
Meeting News

Abrocitinib meets primary, secondary endpoints in atopic dermatitis

October 17, 2019
Abrocitinib, in both 100 mg and 200 mg doses, significantly improved Investigator Global Assessment and Eczema Area and Severity Index-75 scores in…
Meeting News

Bermekimab improves all disease measures of atopic dermatitis in phase 2 study

October 16, 2019
Bermekimab, which neutralizes interleukin-1 alpha, improved all disease measures of atopic dermatitis, including a large reduction in pruritus…
Meeting News

Oral JAK inhibitor improves alopecia areata severity

October 15, 2019
Patients with moderate to severe alopecia areata who were assigned to CTP-543, an oral Janus kinase inhibitor from Concert Pharmaceuticals, achieved…
Meeting News

Tralokinumab may neutralize IL-13 levels in atopic dermatitis

October 14, 2019
Interleukin-13 may be the central cytokine in the skin of patients with atopic dermatitis, and by blocking interleukin-13 with targeted therapies it…
Meeting News

4-year data demonstrate safety, efficacy of Ilumya in plaque psoriasis

October 11, 2019
The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label…
Meeting News

Psoriasis severity affects severity of nonalcoholic fatty liver disease

October 11, 2019
Prospective study data presented at the European Academy of Dermatology and Venereology Congress demonstrated that psoriasis severity is associated…
Healio Jobs